With a New Take on an Old Schizophrenia Drug, LB Pharma Prepares IPO to Fund Phase 3 Test

With a New Take on an Old Schizophrenia Drug, LB Pharma Prepares IPO to Fund Phase 3 Test

LB Pharmaceuticals’ planned IPO will fund late-stage clinical development of LB-102, a once-daily pill designed to improve on the old Sanofi schizophrenia drug Solian. The IPO filing follow a corporate restructuring in May that cut the jobs of LB’s chief financial and scientific officers to streamline operations and extend its cash runway. The post With a New Take on an Old Schizophrenia Drug, LB Pharma Prepares IPO to Fund Phase 3 Test appeared…

LB Pharmaceuticals seeks IPO as cash runs dry for looming Phase 3 schizophrenia trial

The first biotech IPO in six-plus months will be a sharp test of whether investors are truly ready to buy into young biotech companies whose success remains uncertain. On Friday, LB Pharmaceuticals ...